

# Conversions et compétitions entre acides gras essentiels chez l'animal et l'homme

Pr. Philippe LEGRAND

Laboratoire de Biochimie et Nutrition Humaine  
AGROCAMPUS - INRA, Rennes




Avril 2008




- **The pathway**
- **Genetical aspects**
- **$\Delta 6$  desaturase (FADS2) acts at different places**
- **Régulation of  $\Delta 6$  et  $\Delta 5$  desaturases by fatty acids**
- **Limits of DHA biosynthesis**

ANIMALS, PLANTS,  
BACTERIA

ANIMALS



## "Sprecher" pathway



- **The pathway**
- **Genetical aspects**
- **$\Delta 6$  desaturase (FADS2) acts at different places**
- **Régulation of  $\Delta 6$  et  $\Delta 5$  desaturases by fatty acids**
- **Limits of DHA biosynthesis**

## $\Delta 6$ and $\Delta 5$ desaturases

### Cloning and sequencing :

- $\Delta 6$  mouse and human (Cho et al., 1999a)
- $\Delta 6$  rat (Aki et al., 1999)
- $\Delta 5$  human (Cho et al., 1999b; Leonard et al., 2000)

### Existence of a second "human $\Delta 6$ isoform" (70 % homology)


(EMBL, Li et al., not published)

### Second rat " $\Delta 6$ isoform" cloned and sequenced

(EMBL, D'Andréa et al., not published)

### Confirmation of 3 genes FADS1, FADS2, FADS3 on chromosome 11 in human

(Marquardt et al., 2000)




NB :  $\Delta 6$  et  $\Delta 5$  désaturases contain a cytochrome b5 domain

- **The pathway**
- **Genetical aspects**
- **$\Delta 6$  desaturase (FADS2) acts at different places**
- **Régulation of  $\Delta 6$  et  $\Delta 5$  desaturases by fatty acids**
- **Limits of DHA biosynthesis**

# "Sprecher" pathway

Voss et al., 1991



## $\Delta 6$ DESATURASE

ONE

OR

TWO

Competitions between substrates  
(Geiger et al., 1993)  
Déficiences in human fibroblasts  
(Williand et al., 2001)


Certain cells do not synthesize C22:6 n-3  
although they have an active  $\Delta 6$  desaturase  
(Marzo et al., 1996; Chen et al., 1993)

Démonstration that the cloned  $\Delta 6$  is active on both C 18:3 n-3 et le C 24:5 n-3  
(D'Andréa et al., 2002)



- **The pathway**
- **Genetical aspects**
- **$\Delta 6$  desaturase (FADS2) acts at different places**
- **Régulation of  $\Delta 6$  et  $\Delta 5$  desaturases by fatty acids**
- **Limits of DHA biosynthesis**


maintained for their structural et fonctional roles, whatever the nutritional and metabolic status



Lipogenic conditions, fed animal


Fasted conditions, lipolysis

# Rôle de l'acide myristique sur le métabolisme des acides gras polyinsaturés



- ↪ Expression génique ?
- ↪ Modification co ou post traductionnelle ?
- ↪ Autres ?

# Effect of myristic acid on PUFAs composition in the rat *in vivo*



- **The pathway**
- **Genetical aspects**
- **$\Delta 6$  desaturase (FADS2) acts at different places**
- **Régulation of  $\Delta 6$  et  $\Delta 5$  desaturases by fatty acids**
- **Limits of DHA biosynthesis**

## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity

# CONVERSION



- 10 fois moins active chez l'homme que chez le rat  
(Descomps, 2003)
- Organisme entier : conversion < 5 %, probablement < 1%  
(Brenna, 2002; Cunnane, 2001; Crawford, 2004)
- Le DHA plasmatique inhibe la conversion DPA  $\rightarrow$  DHA (Pawloski et al., 2004)
- Meilleure conversion chez la femme que l'homme  
(Burdge et al., 2002)
- Etude avec des traceurs : controverses


	Pawlosky et al., 2001	Goyens et al., 2005
18:3 n-3 $\rightarrow$ 20:5 n-3 :	0.2 %	} 7 % 1% (des 7%)
20:5 n-3 $\rightarrow$ 22:5 n-3 :	63 %	
22:5 n-3 $\rightarrow$ 22:6 n-3 :	23 %	

## Limits of DHA biosynthesis

- **Low activity of the pathway**
- **Doses and sources of C 18:3 n-3**
- **Activity of  $\Delta 6$  desaturase**
- **Competitions inside the n-3 family for the  $\Delta 6$  desaturase**
- **Activity of elongases**
- **Peroxisomal  $\beta$ -oxydation**
- **Retroconversion**
- **Competitions with the n-6 family**
- **Tissu specificity**





# Disponibilité du substrat




60 % en CO<sub>2</sub>, 30 % en acétate  
(Brenna, 2002; Cunnane, 2001)

## Effet dose de l'acide $\alpha$ -linoléinique (ALA) sur sa conversion en dérivés



# Importance des doses d'acide $\alpha$ -linoléique sur la disponibilité du DHA



## Acides gras des lipides du sérum des volontaires (% des acides gras totaux)

Acide gras	Régime "contrôle"		Régime "Lin"
C 16:0	19.5 ± 1.8	*	18.5 ± 1.7
C 18:0	5.9 ± 0.9		5.7 ± 0.8
C 18:1 n-9	22.6 ± 2.0		23.3 ± 2.4
C 18:2 n-6	31.3 ± 3.6		31.6 ± 4.2
C 18:2 cis 9 trans 11	0.28 ± 0.07	**	0.42 ± 0.13
C 18:3 n-3	0.44 ± 0.11	**	0.93 ± 0.30
C 20:4 n-6	7.7 ± 1.1		6.6 ± 1.1
C 20:5 n-3	0.52 ± 0.22	**	0.80 ± 0.17
C 22:5 n-3	0.35 ± 0.08	**	0.45 ± 0.10
C 22:6 n-3	1.51 ± 0.24	*	1.67 ± 0.29
C 18:2 n-6 / C 18:3 n-3	71 ± 23	**	34 ± 12
Σ n-6 / Σ n-3	14.3 ± 2.5	**	10.2 ± 1.8

C 18:3 n-3 (% acides gras)


1.0

2.75

## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity

## Voie faiblement active




### Activités :

- Faibles
- Variables (situations physiologiques et physiopathologiques)
- Synthèse limitée du DHA


## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity



L'acide  $\alpha$ -linoléinique (ALA) est à la fois précurseur et compétiteur pour la synthèse du DHA






## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity

## Activité des élongases



ELOVL2 (human) : plus active pour 20→22 que 22→24

Leonard et al., 2002


**NB :** - Etape 20:5 → 22:5 lente d'après Goyens et al., 2005

- Pas d'accumulation de 24:5 ni de 24:6

## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity


**β-oxydation peroxysomale**



## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity

## Rétroconversion du DHA




- Processus peroxysomal (étape de  $\beta$ -oxydation + enoyl réductase) (Schlenk et al., 1969; Gronn et al., 1991)
- Existe pour la famille n-6 (22:5  $\rightarrow$  20:4) (Phyllis et al., 2000)
- Activité faible (1.4% chez l'homme, Brossard et al., 1996)
- Plus forte si déficit en C20:5 n-3 ( 9%, Conquer et al., 1997)
- Assurer le niveau de C20:5 pour la production des prostaglandines

⇒ Probablement mineure si apport suffisant en C18:3 n-3

## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family..... and oleic acid
- Tissue specificity





### Activités :

- Faibles
  - Variables (situations physiologiques et physiopathologiques)
  - Synthèse limitée du DHA
- ➔ Situations nutritionnelles : excès de n-6, oléique, (trans ?)

# COMPETITION AVEC LES n-6

## ENFANT

**Méta-analyse (Clark et al., 1992) :**

**Par rapport à l'allaitement maternel :**

- ↪ **Déficit de conversion de 50 % quand  $18:2 \text{ n-6} / 18:3 \text{ n-3} > 20$**
- ↪ **Déficit de conversion de 27 % quand  $18:2 \text{ n-6} / 18:3 \text{ n-3} = 5$**

## ADULTE


- ↪ **Réduction de conversion**  
*(Mantzioris et al., 1994; O'Dea et al., 1988)*
- ↪ **50 % de réduction quand  $18:2 \text{ n-6}$  passe de 15 à 30 g / jour**  
*(Emken et al., 1994)*
- ↪ **Conversion inversement corrélée à la quantité de  $C18:2 \text{ n-6}$**   
*(Gibson et al., 2004, Hussein et al., 2005, Lands 2005)*

is the role of the ratio linoleic / linolenic major or minor ?

## Limits of DHA biosynthesis

- Low activity of the pathway
- Doses and sources of C 18:3 n-3
- Activity of  $\Delta 6$  desaturase
- Competitions inside the n-3 family for the  $\Delta 6$  desaturase
- Activity of elongases
- Peroxysomal  $\beta$ -oxydation
- Retroconversion
- Competitions with the n-6 family
- Tissue specificity

## La conversion C18:3 n-3 → C22:6 n-3 serait tissu spécifique



Suggère une conversion désaturation spécifique du cerveau

*(Barcelo-Coblijn et al., 2005)*

$\Delta 6$  et  $\Delta 5$  exprimées dans le cerveau *(Cho et al., 1999)*

Synthèse du DHA dans les astrocytes *(Bernoud et al., 2001)*

Synthèse dans les neurones *(Spector dans Barcelo-Coblijn et al., 2005)*

## **EFFECT OF DIETARY n-3 PUFA DEPRIVATION IN THE RAT:**

**DHA synthesis from  $\alpha$ -linolenic acid by rat brain is unaffected by dietary n-3 deprivation. (15 weeks, 14C  $\alpha$ -linolenic acid)**

*(Igarashi et al., 2007)*

**Dietary n-3 PUFA deprivation for 15 weeks upregulates elongases and desaturase expression in rat liver but not brain**

*(Igarashi et al., 2007)*

**Laboratoire de Biochimie - Nutrition Humaine  
AGROCAMPUS - INRA, Rennes**

<b>P. LEGRAND</b>	<b>Professeur, Directeur</b>
<b>V. RIOUX</b>	<b>Maître de conférences</b>
<b>F. PEDRONO</b>	<b>Maître de conférences</b>
<b>D. CATHELIN</b>	<b>Ingénieur de Recherches</b>
<b>N. MONTHEAN</b>	<b>Technicienne</b>
<b>A. LEBORGNE</b>	<b>Aide technique</b>
<b>K. LOAN</b>	<b>Aide de laboratoire</b>
<b>R. MARION</b>	<b>Aide de laboratoire</b>
<b>M F GAILLARD</b>	<b>Secrétaire</b>